Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Restart tICrH: Timing of Anticoagulation After Traumatic Intracranial Hemorrhage
NCT04229758Phase 3Not yet recruiting
- Sponsor
- University of Texas at Austin
- Start
- Oct 2021
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Atrial fibrillation (AFib) and venous thromboembolism (VTE) (3 arms), sponsored by University of Texas at Austin. Primary endpoint: 60-day composite of thromboembolic events and bleeding events. Planned start Oct 2021; status: not yet recruiting.
02
Conditions
Atrial fibrillation (AFib)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT04229758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229758.